{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:17:00Z","timestamp":1777421820240,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T00:00:00Z","timestamp":1539993600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13000-018-0760-6","type":"journal-article","created":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T15:28:21Z","timestamp":1540049301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue"],"prefix":"10.1186","volume":"13","author":[{"given":"Kerstin","family":"Hartmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kornelia","family":"Schlombs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Laible","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"G\u00fcrtler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugur","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Anton","family":"Lehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,20]]},"reference":[{"key":"760_CR1","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nm1764","volume":"14","author":"G Finak","year":"2008","unstructured":"Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14:518\u201327. \n                    https:\/\/doi.org\/10.1038\/nm1764 \n                    \n                  .","journal-title":"Nat Med"},{"key":"760_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00428-012-1357-1","volume":"462","author":"V Kotoula","year":"2012","unstructured":"Kotoula V, Kalogeras KT, Kouvatseas G, Televantou D, Kronenwett R, Wirtz RM, et al. Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research. Virchows Arch. 2012;462:141\u201354. \n                    https:\/\/doi.org\/10.1007\/s00428-012-1357-1 \n                    \n                  .","journal-title":"Virchows Arch"},{"key":"760_CR3","doi-asserted-by":"publisher","unstructured":"Ma X-J, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 2009;11. \n                    https:\/\/doi.org\/10.1186\/bcr2222 \n                    \n                  .","DOI":"10.1186\/bcr2222"},{"key":"760_CR4","doi-asserted-by":"publisher","unstructured":"Schobesberger M, Baltzer A, Oberli A, Kappeler A, Gugger M, Burger H, et al. Gene expression variation between distinct areas of breast cancer measured from paraffin-embedded tissue cores. BMC Cancer. 2008;8. \n                    https:\/\/doi.org\/10.1186\/1471-2407-8-343 \n                    \n                  .","DOI":"10.1186\/1471-2407-8-343"},{"key":"760_CR5","doi-asserted-by":"publisher","first-page":"815","DOI":"10.5858\/arpa.2016-0051-RA","volume":"140","author":"IS Hagemann","year":"2016","unstructured":"Hagemann IS. Molecular testing in breast Cancer: a guide to current practices. Arch Pathol Lab Med. 2016;140:815\u201324. \n                    https:\/\/doi.org\/10.5858\/arpa.2016-0051-RA \n                    \n                  .","journal-title":"Arch Pathol Lab Med"},{"key":"760_CR6","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1043\/1543-2165-134.6.907","volume":"134","author":"ME Hammond","year":"2010","unstructured":"Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134:907\u201322. \n                    https:\/\/doi.org\/10.1043\/1543-2165-134.6.907 \n                    \n                  .","journal-title":"Arch Pathol Lab Med"},{"key":"760_CR7","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1093\/jnci\/djt306","volume":"105","author":"MY Polley","year":"2013","unstructured":"Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, et al. An international Ki67 reproducibility study. J Natl Cancer Inst. 2013;105:1897\u2013906. \n                    https:\/\/doi.org\/10.1093\/jnci\/djt306 \n                    \n                  .","journal-title":"J Natl Cancer Inst"},{"key":"760_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1136\/jclinpath-2014-202571","volume":"68","author":"EA Rakha","year":"2015","unstructured":"Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, et al. Updated UK recommendations for HER2 assessment in breast cancer. J Clin Pathol. 2015;68:93\u20139. \n                    https:\/\/doi.org\/10.1136\/jclinpath-2014-202571 \n                    \n                  .","journal-title":"J Clin Pathol"},{"key":"760_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037379","volume":"7","author":"Z Varga","year":"2012","unstructured":"Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, Noske A, et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss working Group of Breast- and Gynecopathologists. PLoS One. 2012;7:e37379. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0037379 \n                    \n                  .","journal-title":"PLoS One"},{"key":"760_CR10","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1158\/1078-0432.ccr-10-1369","volume":"17","author":"K Graham","year":"2010","unstructured":"Graham K, Ge X, de las Morenas A, Tripathi A, Rosenberg CL. Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically Normal breast epithelium. Clin Cancer Res. 2010;17:236\u201346. \n                    https:\/\/doi.org\/10.1158\/1078-0432.ccr-10-1369 \n                    \n                  .","journal-title":"Clin Cancer Res"},{"key":"760_CR11","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1073\/pnas.0931261100","volume":"100","author":"XJ Ma","year":"2003","unstructured":"Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci. 2003;100:5974\u20139. \n                    https:\/\/doi.org\/10.1073\/pnas.0931261100 \n                    \n                  .","journal-title":"Proc Natl Acad Sci"},{"key":"760_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00428-014-1652-0","volume":"465","author":"C Poremba","year":"2014","unstructured":"Poremba C, Uhlendorff J, Pfitzner BM, Hennig G, Bohmann K, Bojar H, et al. Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer. Virchows Arch. 2014;465:409\u201317. \n                    https:\/\/doi.org\/10.1007\/s00428-014-1652-0 \n                    \n                  .","journal-title":"Virchows Arch"},{"key":"760_CR13","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast Cancer 2013. Ann Oncol. 2013;24:2206\u201323. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdt303 \n                    \n                  .","journal-title":"Ann Oncol"},{"key":"760_CR14","doi-asserted-by":"publisher","unstructured":"Laible M, Schlombs K, Kaiser K, Veltrup E, Herlein S, Lakis S, et al. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer. 2016;16. \n                    https:\/\/doi.org\/10.1186\/s12885-016-2476-x \n                    \n                  .","DOI":"10.1186\/s12885-016-2476-x"},{"key":"760_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature10098","volume":"473","author":"B Schwanh\u00e4usser","year":"2011","unstructured":"Schwanh\u00e4usser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Global quantification of mammalian gene expression control. Nature. 2011;473:337\u201342. \n                    https:\/\/doi.org\/10.1038\/nature10098 \n                    \n                  .","journal-title":"Nature"},{"key":"760_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/1479-5876-10-212","volume":"10","author":"G Fountzilas","year":"2012","unstructured":"Fountzilas G, Christodoulou C, Bobos M, Kotoula V, Eleftheraki AG, Xanthakis I, et al. Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab. J Transl Med. 2012;10:212. \n                    https:\/\/doi.org\/10.1186\/1479-5876-10-212 \n                    \n                  .","journal-title":"J Transl Med"},{"key":"760_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088401","volume":"9","author":"EB Schleifman","year":"2014","unstructured":"Schleifman EB, Desai R, Spoerke JM, Xiao Y, Wong C, Abbas I, et al. Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers. PLoS One. 2014;9:e88401. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0088401 \n                    \n                  .","journal-title":"PLoS One"},{"key":"760_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10549-014-3163-8","volume":"148","author":"TR Wilson","year":"2014","unstructured":"Wilson TR, Xiao Y, Spoerke JM, Fridlyand J, Koeppen H, Fuentes E, et al. Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples. Breast Cancer Res Treat. 2014;148:315\u201325. \n                    https:\/\/doi.org\/10.1007\/s10549-014-3163-8 \n                    \n                  .","journal-title":"Breast Cancer Res Treat"},{"key":"760_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ejca.2017.01.017","volume":"75","author":"MJ Duffy","year":"2017","unstructured":"Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, et al. Clinical use of biomarkers in breast cancer: updated guidelines from the European group on tumor markers (EGTM). Eur J Cancer. 2017;75:284\u201398. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2017.01.017 \n                    \n                  .","journal-title":"Eur J Cancer"},{"key":"760_CR20","doi-asserted-by":"publisher","unstructured":"Sinn H-P, Schneeweiss A, Keller M, Schlombs K, Laible M, Seitz J, et al. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. BMC Cancer. 2017;17. \n                    https:\/\/doi.org\/10.1186\/s12885-017-3111-1 \n                    \n                  .","DOI":"10.1186\/s12885-017-3111-1"},{"key":"760_CR21","doi-asserted-by":"publisher","unstructured":"Varga Z, Lebeau A, Bu H, Hartmann A, Penault-Llorca F, Guerini-Rocco E, et al. An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper\u00ae. Breast Cancer Res. 2017;19. \n                    https:\/\/doi.org\/10.1186\/s13058-017-0848-z \n                    \n                  .","DOI":"10.1186\/s13058-017-0848-z"},{"key":"760_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10549-016-3835-7","volume":"157","author":"RM Wirtz","year":"2016","unstructured":"Wirtz RM, Sihto H, Isola J, Heikkil\u00e4 P, Kellokumpu-Lehtinen P-L, Auvinen P, et al. Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry. Breast Cancer Res Treat. 2016;157:437\u201346. \n                    https:\/\/doi.org\/10.1007\/s10549-016-3835-7 \n                    \n                  .","journal-title":"Breast Cancer Res Treat"},{"key":"760_CR23","doi-asserted-by":"publisher","unstructured":"Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, et al. Comparison of molecular phenotypes of ductal carcinoma in situand invasive breast cancer. Breast Cancer Res. 2008;10. \n                    https:\/\/doi.org\/10.1186\/bcr2128 \n                    \n                  .","DOI":"10.1186\/bcr2128"},{"key":"760_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1055\/s-0033-1360263","volume":"74","author":"A Waldmann","year":"2014","unstructured":"Waldmann A, Anzeneder T, Katalinic A. Patients and methods of the PATH biobank - a resource for breast Cancer research. Geburtshilfe Frauenheilkd. 2014;74:361\u20139. \n                    https:\/\/doi.org\/10.1055\/s-0033-1360263 \n                    \n                  .","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"760_CR25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2741\/3617","volume":"15","author":"PR Pandey","year":"2010","unstructured":"Pandey PR. Role of myoepithelial cells in breast tumor progression. Front Biosci. 2010;15:226. \n                    https:\/\/doi.org\/10.2741\/3617 \n                    \n                  .","journal-title":"Front Biosci"},{"key":"760_CR26","unstructured":"Kennedy S, Oswald N. PCR troubleshooting and optimization : the essential guide. Norfolk, UK: Caister Academic Press; 2011. vii, 235 p., 4 p. of plates p."},{"key":"760_CR27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1586\/14737159.2014.901154","volume":"14","author":"A Stahlberg","year":"2014","unstructured":"Stahlberg A, Kubista M. The workflow of single-cell expression profiling using quantitative real-time PCR. Expert Rev Mol Diagn. 2014;14:323\u201331. \n                    https:\/\/doi.org\/10.1586\/14737159.2014.901154 \n                    \n                  .","journal-title":"Expert Rev Mol Diagn"},{"key":"760_CR28","first-page":"123","volume-title":"Basic histology","author":"J LCUa","year":"2005","unstructured":"LCUa J, Carneiro J. Basic histology. 11th ed. New York, USA: McGraw Hill; 2005. p. 123\u20137.","edition":"11"},{"key":"760_CR29","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1089\/bio.2011.0034","volume":"9","author":"BC Mee","year":"2011","unstructured":"Mee BC, Carroll P, Donatello S, Connolly E, Griffin M, Dunne B, et al. Maintaining breast Cancer specimen integrity and individual or simultaneous extraction of quality DNA, RNA, and proteins from Allprotect-stabilized and nonstabilized tissue samples. Biopreservation and Biobanking. 2011;9:389\u201398. \n                    https:\/\/doi.org\/10.1089\/bio.2011.0034 \n                    \n                  .","journal-title":"Biopreservation and Biobanking"},{"key":"760_CR30","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00428-013-1486-1","volume":"463","author":"T Tramm","year":"2013","unstructured":"Tramm T, Hennig G, Kyndi M, Alsner J, S\u00f8rensen FB, Myhre S, et al. Reliable PCR quantitation of estrogen, progesterone and ERBB2 receptor mRNA from formalin-fixed, paraffin-embedded tissue is independent of prior macro-dissection. Virchows Arch. 2013;463:775\u201386. \n                    https:\/\/doi.org\/10.1007\/s00428-013-1486-1 \n                    \n                  .","journal-title":"Virchows Arch"},{"key":"760_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1200\/jco.2012.30.27_suppl.32","volume":"30","author":"G Viale","year":"2012","unstructured":"Viale G, Slaets L, De Snoo F, van 't Veer LJ, Rutgers EJ, Bogaerts J, et al. Comparison of molecular (BluePrint and MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041\/BIG 3-04 (MINDACT) trial. J Clin Oncol. 2012;30:32. \n                    https:\/\/doi.org\/10.1200\/jco.2012.30.27_suppl.32 \n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"760_CR32","doi-asserted-by":"publisher","unstructured":"Elloumi F, Hu Z, Li Y, Parker JS, Gulley ML, Amos KD, et al. Systematic Bias in genomic classification due to contaminating non-neoplastic tissue in breast tumor samples. BMC Med Genet. 2011;4. \n                    https:\/\/doi.org\/10.1186\/1755-8794-4-54 \n                    \n                  .","DOI":"10.1186\/1755-8794-4-54"},{"issue":"8","key":"760_CR33","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41374-018-0064-1","volume":"98","author":"Swati Gupta","year":"2018","unstructured":"Gupta S, Mani NR, Carvajal-Hausdorf DE, Bossuyt V, Ho K, Weidler J, et al. Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC\/FISH in breast cancer. Lab Investig. 2018. \n                    https:\/\/doi.org\/10.1038\/s41374-018-0064-1 \n                    \n                  .","journal-title":"Laboratory Investigation"},{"key":"760_CR34","doi-asserted-by":"publisher","unstructured":"Nielsen T, Wallden B, Schaper C, Ferree S, Liu S, Gao D, et al. Analytical validation of the PAM50-based Prosigna breast Cancer prognostic gene signature assay and nCounter analysis system using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer. 2014;14. \n                    https:\/\/doi.org\/10.1186\/1471-2407-14-177 \n                    \n                  .","DOI":"10.1186\/1471-2407-14-177"},{"key":"760_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-188","volume":"9","author":"A Kohrmann","year":"2009","unstructured":"Kohrmann A, Kammerer U, Kapp M, Dietl J, Anacker J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer. 2009;9:188. \n                    https:\/\/doi.org\/10.1186\/1471-2407-9-188 \n                    \n                  .","journal-title":"BMC Cancer"},{"key":"760_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1677\/jme.0.0330035","volume":"33","author":"C Palmieri","year":"2004","unstructured":"Palmieri C, Saji S, Sakaguchi H, Cheng G, Sunters A, O'Hare MJ, et al. The expression of oestrogen receptor (ER)-beta and its variants, but not ERalpha, in adult human mammary fibroblasts. J Mol Endocrinol. 2004;33:35\u201350 \n                    https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15291741\n                    \n                  .","journal-title":"J Mol Endocrinol"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-018-0760-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13000-018-0760-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-018-0760-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T23:20:17Z","timestamp":1571527217000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-018-0760-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,20]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["760"],"URL":"https:\/\/doi.org\/10.1186\/s13000-018-0760-6","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,20]]},"assertion":[{"value":"4 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study consisted of 49 human FFPE invasive breast carcinoma samples. Thirteen cases were derived from the Institute of Molecular Gynecological Oncology, Mainz, Germany. The use of archived samples was approved by the ethics committee of the Landes\u00e4rztekammer Rheinland-Pfalz (837.139.05 (4797)). Thirty one cases were obtained from PATH Biobank (Patients\u02bc Tumour Bank of Hope), Munich, Germany []. Patients provided individual, written informed consent for the storage of samples and data, follow-up contact, and further use of samples and data for research purposes. The processes of PATH Biobank have been approved by the ethics committee of the medical faculty of the University of Bonn (255\/06). Five additional cases were purchased from commercial vendors (Asterand Biosciences, Detroit, USA MI; Proteogenex, Culver City, USA CA).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"US is founder and CEO of BioNTech Diagnostics GmbH. KH, KS, ML and CG are employees of BioNTech Diagnostics GmbH. MS and HAL declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"83"}}